Cytokinetics (CYTK)

$48.66 -0.63 (-1.28%)
Market Cap 5.69B
Revenue (ttm) 18.47M
Net Income (ttm) -589.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,191.82%
Debt to Equity Ratio -0.47
Volume 3,733,154
Avg Vol 2,108,358
Day's Range N/A - N/A
Shares Out 119.66M
Stochastic %K 28%
Beta 0.62
Analysts Strong Sell
Price Target $75.16

Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It a...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 624 3000
Address:
350 Oyster Point Boulevard, South San Francisco, United States
BigSqueezeComing
BigSqueezeComing Sep. 19 at 12:59 PM
$CYTK Cytokinetics, Incorporated Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 17, 2025 to Discuss Your Rights - CYTK By PR Newswire | September 19, 2025, 8:45 AM
0 · Reply
MrFastScalp
MrFastScalp Sep. 19 at 6:05 AM
FastScalp® Options Trade Alert (Actionable) | Buy $CYTK Oct 17 $50 Call | Enter: $2.52 Exit: $3.65 | Profit: 45.32% ROI | https://fastscalp.com/scalps
0 · Reply
BigSqueezeComing
BigSqueezeComing Sep. 18 at 8:08 PM
$CYTK is 51 possible
0 · Reply
BigSqueezeComing
BigSqueezeComing Sep. 18 at 8:08 PM
$CYTK SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 15, 2025 it granted stock options to purchase an aggregate of 39,790 shares of common stock and 26,822 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 11 employees, whose employment commenced in August and September 2025 as a material inducement to their employment.
0 · Reply
BigSqueezeComing
BigSqueezeComing Sep. 18 at 8:08 PM
$CYTK hidden gem
0 · Reply
BigSqueezeComing
BigSqueezeComing Sep. 18 at 8:07 PM
$CYTK Loade heavy
0 · Reply
BigSqueezeComing
BigSqueezeComing Sep. 18 at 8:07 PM
$CYTK Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) By Cytokinetics, Incorporated | September 18, 2025, 4:00 PM
0 · Reply
I_am_Sparta
I_am_Sparta Sep. 18 at 2:57 PM
$CYTK Short it to single Digits
2 · Reply
Market_Max
Market_Max Sep. 18 at 12:39 PM
$CYTK nHCM long term data - confidence building data to be unveiled September 28 for the nHCM cohort - definitive efficacy proof will come in 2026 from pivotal phase 3 ACACIA study.
1 · Reply
I_am_Sparta
I_am_Sparta Sep. 17 at 7:58 PM
$CYTK pos....only short all @pharmdca stonks to delisting $VKTX $DAWN $IOVA
0 · Reply
Latest News on CYTK
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Sep 19, 2025, 10:18 AM EDT - 6 hours ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Cytokinetics, Inc. Investigated by the Portnoy Lawfirm

Sep 18, 2025, 4:23 PM EDT - 1 day ago

Cytokinetics, Inc. Investigated by the Portnoy Lawfirm

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Sep 18, 2025, 4:00 PM EDT - 1 day ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Cytokinetics, Incorporated (CYTK)

Sep 18, 2025, 10:30 AM EDT - 1 day ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Cytokinetics, Incorporated (CYTK)

Cytokinetics Announces Three Upcoming Presentations at the HFSA Annual Scientific Meeting 2025

Sep 18, 2025, 7:30 AM EDT - 1 day ago

Cytokinetics Announces Three Upcoming Presentations at the HFSA Annual Scientific Meeting 2025

Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes

Sep 16, 2025, 11:45 PM EDT - 2 days ago

Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes

Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes

Sep 16, 2025, 4:02 PM EDT - 3 days ago

Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes

Cytokinetics, Incorporated (CYTK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 9, 2025, 2:04 PM EDT - 10 days ago

Cytokinetics, Incorporated (CYTK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

Sep 3, 2025, 3:32 PM EDT - 16 days ago

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

ARGX BBH BMRN IBB XBI

Cytokinetics, Incorporated (CYTK) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 2, 2025, 5:43 PM EDT - 16 days ago

Cytokinetics, Incorporated (CYTK) Presents At Citi's Biopharma Back To School Conference Transcript

Cytokinetics: Game-Changing Data Confirms Best-In-Class Potential

Sep 2, 2025, 2:07 PM EDT - 17 days ago

Cytokinetics: Game-Changing Data Confirms Best-In-Class Potential

Cytokinetics, Incorporated - Exploring The Changing Treatment Paradigm Transcript

Sep 2, 2025, 12:23 PM EDT - 17 days ago

Cytokinetics, Incorporated - Exploring The Changing Treatment Paradigm Transcript

Cytokinetics Stock Jumps. The Biotech's Heart Drug Wows.

Sep 2, 2025, 11:09 AM EDT - 17 days ago

Cytokinetics Stock Jumps. The Biotech's Heart Drug Wows.

Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025

Aug 31, 2025, 12:10 PM EDT - 19 days ago

Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025

Cytokinetics' drug more effective for heart disease symptoms than standard-of-care

Aug 30, 2025, 3:27 AM EDT - 20 days ago

Cytokinetics' drug more effective for heart disease symptoms than standard-of-care

Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine

Aug 30, 2025, 3:18 AM EDT - 20 days ago

Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine

Cytokinetics to Participate in September Investor Conferences

Aug 27, 2025, 4:00 PM EDT - 23 days ago

Cytokinetics to Participate in September Investor Conferences

Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025

Aug 25, 2025, 7:30 AM EDT - 25 days ago

Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025

Cytokinetics: Specialty Franchise With Aficamten And Ulacamten

Aug 20, 2025, 8:00 AM EDT - 4 weeks ago

Cytokinetics: Specialty Franchise With Aficamten And Ulacamten

Cytokinetics Names Jim Daly to Board of Directors

Aug 20, 2025, 7:30 AM EDT - 4 weeks ago

Cytokinetics Names Jim Daly to Board of Directors

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 19, 2025, 4:00 PM EDT - 4 weeks ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics, Incorporated (CYTK) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 4:28 PM EDT - 6 weeks ago

Cytokinetics, Incorporated (CYTK) Q2 2025 Earnings Call Transcript

Cytokinetics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 7, 2025, 4:00 PM EDT - 6 weeks ago

Cytokinetics Reports Second Quarter 2025 Financial Results and Provides Business Update

Cytokinetics Merits A Speculative Buy Rating

Jul 25, 2025, 1:23 PM EDT - 2 months ago

Cytokinetics Merits A Speculative Buy Rating

Cytokinetics to Announce Second Quarter Results On August 7, 2025

Jul 24, 2025, 4:00 PM EDT - 2 months ago

Cytokinetics to Announce Second Quarter Results On August 7, 2025

Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program

Jun 10, 2025, 7:30 AM EDT - 3 months ago

Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program

Cytokinetics to Participate in the Jefferies Global Healthcare Conference

May 29, 2025, 4:00 PM EDT - 4 months ago

Cytokinetics to Participate in the Jefferies Global Healthcare Conference

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Reach Out

May 20, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Shareholders to Learn More About the Investigation

May 19, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Shareholders to Learn More About the Investigation

Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

May 18, 2025, 10:00 AM EDT - 4 months ago

Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress

May 18, 2025, 8:00 AM EDT - 4 months ago

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress

Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Shareholders to Inquire about Securities Investigation

May 16, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Shareholders to Inquire about Securities Investigation

BigSqueezeComing
BigSqueezeComing Sep. 19 at 12:59 PM
$CYTK Cytokinetics, Incorporated Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 17, 2025 to Discuss Your Rights - CYTK By PR Newswire | September 19, 2025, 8:45 AM
0 · Reply
MrFastScalp
MrFastScalp Sep. 19 at 6:05 AM
FastScalp® Options Trade Alert (Actionable) | Buy $CYTK Oct 17 $50 Call | Enter: $2.52 Exit: $3.65 | Profit: 45.32% ROI | https://fastscalp.com/scalps
0 · Reply
BigSqueezeComing
BigSqueezeComing Sep. 18 at 8:08 PM
$CYTK is 51 possible
0 · Reply
BigSqueezeComing
BigSqueezeComing Sep. 18 at 8:08 PM
$CYTK SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 15, 2025 it granted stock options to purchase an aggregate of 39,790 shares of common stock and 26,822 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 11 employees, whose employment commenced in August and September 2025 as a material inducement to their employment.
0 · Reply
BigSqueezeComing
BigSqueezeComing Sep. 18 at 8:08 PM
$CYTK hidden gem
0 · Reply
BigSqueezeComing
BigSqueezeComing Sep. 18 at 8:07 PM
$CYTK Loade heavy
0 · Reply
BigSqueezeComing
BigSqueezeComing Sep. 18 at 8:07 PM
$CYTK Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) By Cytokinetics, Incorporated | September 18, 2025, 4:00 PM
0 · Reply
I_am_Sparta
I_am_Sparta Sep. 18 at 2:57 PM
$CYTK Short it to single Digits
2 · Reply
Market_Max
Market_Max Sep. 18 at 12:39 PM
$CYTK nHCM long term data - confidence building data to be unveiled September 28 for the nHCM cohort - definitive efficacy proof will come in 2026 from pivotal phase 3 ACACIA study.
1 · Reply
I_am_Sparta
I_am_Sparta Sep. 17 at 7:58 PM
$CYTK pos....only short all @pharmdca stonks to delisting $VKTX $DAWN $IOVA
0 · Reply
buddyopalosam
buddyopalosam Sep. 17 at 7:57 PM
$CYTK going to 42 in the short term. Buy there.
0 · Reply
Red6213
Red6213 Sep. 17 at 7:52 PM
$CYTK There are no messages in the feed with almost 6 million shares being traded today. Interesting! Looks like everyone is holding for long term and is not worried about CYTK.
0 · Reply
BiotechBonesaw
BiotechBonesaw Sep. 17 at 2:57 AM
$VNDA I swear to God if I see one more late night Vanda commercial I may make VNDA my first short ever on principal. Your company is not doing well enough to waste money. @Proposition_Joe & @Biotech_Beast know that millions of dollars spent on DTC are better spent getting clinical trials developed, enrolled, and approved. ⏰ If I were a Vanda shareholder I would be blasting them constantly for wasting shareholder funds on that crap instead of getting critical clinical trials advanced 😡 $TNXP $IMRX $CYTK $BHVN aren’t wasting dollars on that bullshit. Does your leadership think clinical development is cheap or easy? It isn’t 🏦
0 · Reply
Red6213
Red6213 Sep. 16 at 8:59 PM
$CYTK will the stock price go down with 550 million offering? what do you think it will be tomorrow?
3 · Reply
DonCorleone77
DonCorleone77 Sep. 16 at 8:08 PM
$CYTK Cytokinetics announces private placement of $550M of convertible senior notes
0 · Reply
SelfMafia
SelfMafia Sep. 16 at 8:07 PM
$CYTK Cytokinetics Announces Proposed Private Placement of $550 Million of Convertible Senior Notes
0 · Reply
jrdicker
jrdicker Sep. 16 at 8:06 PM
$CYTK yawn :-) https://finance.yahoo.com/news/cytokinetics-announces-proposed-private-placement-200200324.html
0 · Reply
snipethad
snipethad Sep. 15 at 7:48 AM
$CYTK Demand-driven recovery potential; inventory and supply chain are key
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 13 at 4:33 AM
Enter: $CYTK OCT 17 2025 $55 CALLS Buy in Price: $2.30 - $2.30 Take Profit: $3.27 Stop Bleeding: $2.02 ROI Potential: 42% Exit Within: 71 Minutes https://moneygroup.us/alerts
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 12 at 5:14 AM
Enter: $CYTK OCT 17 2025 $55 CALLS Buy in Price: $2.25 - $2.30 Take Profit: $3.08 Stop Bleeding: $1.98 ROI Potential: 37% Exit Within: 51 Minutes https://moneygroup.us/alerts
0 · Reply
MoneyMaker1244
MoneyMaker1244 Sep. 11 at 11:27 PM
$RAPP $250M raised @ $26.00 Insider purchase @$22.60 $RAPP surge when offering closes? Like $ONDS ?? $XBI $TVTX $CYTK
2 · Reply
Machiaveltrade
Machiaveltrade Sep. 11 at 9:05 PM
$CYTK add on every dip
0 · Reply